文献速递糖尿病

速效门冬胰岛素对比门冬胰岛素联合德谷胰岛素在儿童及青少年1型糖尿病中的疗效与安全性:onset 7试验

Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
PubMed 文献 · Diabetes Care · 2019-05-10

这项为期26周的多中心随机双盲试验纳入1至<18岁1型糖尿病患儿,比较餐时速效门冬胰岛素、餐时门冬胰岛素及餐后速效门冬胰岛素联合德谷胰岛素的疗效与安全性。结果显示餐时速效门冬胰岛素在HbA1c降幅上优于门冬胰岛素,且未增加低血糖风险。

要点

  • 餐时速效门冬胰岛素联合德谷胰岛素较门冬胰岛素显著改善HbA1c。
  • 餐后速效门冬胰岛素对HbA1c非劣效于门冬胰岛素。
  • 各组严重或血糖确证低血糖总体发生率无显著差异。

核心结论

  • 在儿童及青少年1型糖尿病患者中,餐时和餐后速效门冬胰岛素联合德谷胰岛素均提供有效血糖控制,且与门冬胰岛素相比未增加安全性风险。
  • 餐时速效门冬胰岛素相比门冬胰岛素提供更优的HbA1c控制。

研究设计与样本

  • Treat-to-target、26周、多中心试验,经过12周导入期后随机分组。
  • 受试者为1至<18岁1型糖尿病患者,随机接受双盲餐时速效门冬胰岛素(n=260)、餐时门冬胰岛素(n=258)或开放标签餐后速效门冬胰岛素(n=259)。
  • 主要终点为治疗26周后HbA1c相对基线的变化。

主要发现

  • 第26周时,餐时和餐后速效门冬胰岛素相对于门冬胰岛素在HbA1c相对基线变化方面均非劣效(非劣效界值0.4%,P<0.001)。
  • 餐时速效门冬胰岛素相比门冬胰岛素有统计学显著优势(估计治疗差异-0.17% [95%CI -0.30; -0.03],-1.82 mmol/mol [-3.28; -0.36];P=0.014)。
  • 餐后1小时血糖增幅相对基线变化在早餐、主晚餐及所有餐次均显著支持餐时速效门冬胰岛素优于门冬胰岛素(所有P<0.01)。
  • 严重或血糖确证低血糖总体发生率未观察到统计学显著差异。
  • 每日总胰岛素剂量均值:餐时速效门冬胰岛素0.92 units/kg,餐后速效门冬胰岛素0.92 units/kg,餐时门冬胰岛素0.88 units/kg。

关键数值与推荐

  • 非劣效界值为HbA1c变化0.4%。
  • 餐时速效门冬胰岛素对比门冬胰岛素的估计治疗差异为-0.17% [95%CI -0.30; -0.03](-1.82 mmol/mol [-3.28; -0.36]),P=0.014。
  • 餐后1小时血糖增幅在早餐、主晚餐及所有餐次比较的P值均<0.01(支持餐时速效门冬胰岛素)。

临床怎么用

  • 对于1型糖尿病儿童及青少年,餐时速效门冬胰岛素联合德谷胰岛素可作为改善HbA1c的餐时胰岛素选择。
  • 餐后速效门冬胰岛素联合德谷胰岛素提供与门冬胰岛素相当的HbA1c控制,可作为替代给药时机。
  • 速效门冬胰岛素未增加严重或血糖确证低血糖的总体发生率,安全性特征与门冬胰岛素相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To confirm efficacy and safety of fast-acting insulin aspart (faster aspart) versus insulin aspart (IAsp), both with basal insulin degludec, in a pediatric population with type 1 diabetes. RESEARCH DESIGN AND METHODS: After a 12-week run-in, this treat-to-target, 26-week, multicenter trial randomized participants (1 to <18 years) to double-blind mealtime faster aspart (n = 260), mealtime IAsp (n = 258), or open-label postmeal faster aspart (n = 259). The primary end point was change from baseline in glycated hemoglobin (HbA1c) after 26 weeks of treatment. All available information regardless of treatment discontinuation was used for the evaluation of treatment effect. RESULTS: At week 26, mealtime and postmeal faster aspart were noninferior to IAsp regarding change from baseline in HbA1c (P < 0.001 for noninferiority [0.4% margin]), with a statistically significant difference in favor of mealtime faster aspart (estimated treatment difference -0.17% [95% CI -0.30; -0.03], -1.82 mmol/mol [-3.28; -0.36]; P = 0.014). Change from baseline in 1-h postprandial glucose increment significantly favored mealtime faster aspart versus IAsp at breakfast, main evening meal, and over all meals (P < 0.01 for all). No statistically significant differences in the overall rate of severe or blood glucose-confirmed hypoglycemia were observed. Mean total daily insulin dose was 0.92 units/kg for mealtime faster aspart, 0.92 units/kg for postmeal faster aspart, and 0.88 units/kg for mealtime IAsp. CONCLUSIONS: In children and adolescents with type 1 diabetes, mealtime and postmeal faster aspart with insulin degludec provided effective glycemic control with no additional safety risks versus IAsp. Mealtime faster aspart provided superior HbA1c control compared with IAsp.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Bode BW, Iotova V, Kovarenko M, et al. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial. Diabetes Care. 2019. PMID: 31076415. doi:10.2337/dc19-0009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。